At what enterprise value was EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquired in 2017?

During the acquisition of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS by PERKINELMER in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS when it was acquired by PERKINELMER?

The estimated EV/EBITDA multiple for EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS at the time of the deal?

The revenue of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS at the time of the deal is estimated to be in the range of 250M - 500M USD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS during the acquisition?

EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS's EBITDA is estimated to be in the range of 50M - 100M USD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: http://www.bio-advance.com/documents/communique/Communiqu%C3%A9%20PerkinElmer.pdf

← DATABASE

Home Database Healthcare & PharmaEUROIMMUN MEDICAL LABORATORY DIAGNOSTICS

12/2017

EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquired by PERKINELMER

GERMANY Life Sciences / Medical Devices / Diagnostic Equipment EV 1b - 4b USD

Context

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally. The strategic rationale includes leveraging EUROIMMUN’s high-growth profile (averaging 19% revenue growth over five years) to accelerate PerkinElmer’s overall earnings. Additionally, the acquisition allows PerkinElmer to drive EUROIMMUN’s specialized solutions through its well-established U.S. commercial channels.

EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

EUROIMMUN is a global leader in autoimmune testing and an emerging provider of infectious disease and allergy diagnostics. Headquartered in Europe, the organization leverages deep expertise across immunology, cell biology, biochemistry, and molecular biology to develop advanced detection technologies. It manufactures high-quality diagnostic reagents and instruments used by medical laboratories worldwide to accurately identify antibodies and diagnose a wide array of conditions. Boasting a massive international footprint, the enterprise generates the vast majority of its revenue overseas, particularly across Asian and EMEA markets, serving customers in dozens of countries. Supported by a large global workforce and a decades-long history of continuous scientific innovation, the firm stands as a premier technological pillar in the specialized in-vitro diagnostics sector.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2017

2016

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2018	PERMIRA	CORIN GROUP	UNITED KINGDOM	Life Sciences	Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni)
05/2018	NN	PARAGON MEDICAL	UNITED STATES	Life Sciences	The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets
10/2017	CVC	SEBIA	FRANCE	Life Sciences	CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.
10/2017	UI INVESTISSEMENT / BPIFRANCE	THERADIAL	FRANCE	Life Sciences	Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board
09/2017	FRESENIUS	NXSTAGE MEDICAL	UNITED STATES	Life Sciences	Fresenius Medical Care announced a definitive agreement to acquire all outstanding shares of NxStage Medical. The acquisition is strategically central to FMC's 2020 strategic initiative, positioning the combined entity as a global leader in home dialysis by integrating NxStage's System One platform into FMC's vertically integrated dialysis ecosystem
06/2017	EQT PARTNERS	OTTOBOCK	GERMANY	Life Sciences	EQT VII has entered into an agreement to acquire a 20% minority stake in Ottobock, as part of a strategic partnership aimed at supporting Ottobock's international growth ambitions, driving its strategic objectives, and potentially preparing the company for a future initial public offering (IPO) in the medium term
06/2017	CHARTERHOUSE	SERB	BELGIUM	Life Sciences	This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership
05/2017	PAI PARTNERS	ELITECH GROUP	FRANCE	Life Sciences	Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector
04/2017	BAIN CAPITAL / CINVEN	STADA	GERMANY	Life Sciences	The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5
04/2017	NORDSON CORPORATION	VENTION ADVANCED TECHNOLOGIES	UNITED KINGDOM	Life Sciences	The acquisition of Vention Advanced Technologies by Nordson Corporation signifies a major step in the group’s expansion into the high-growth medtech sector. The strategic logic of this transaction hinges on a "market-balancing" maneuver, merging the target’s industry-leading technical operational depth in interventional delivery systems with the buyer’s established scale in precision fluid management

REFERENCES

Valuation range: EV 1b - 4b USD

Revenue range: 250M - 500M USD

EBITDA range: 50M - 100M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS by PERKINELMER are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: euroimmun medical laboratory diagnostics

Acquirer: perkinelmer